Discriminative ability of EQ-5D-3L index scores at week 52 to separate belimumab from placebo in the pooled BLISS study population. The y-axis denotes the OR and 95% CI for discriminating between belimumab (10 mg/kg) and placebo, while the x-axis denotes the EQ-5D-3L index scores at week 52 multiplied by 100. Cut-offs yielding statistical significance are denoted by one (P < 0.05), two (P < 0.01) or three asterisks (P < 0.001). Each dot is a unique EQ-5D-3L index cut-off, and the grey area or the corresponding vertical whiskers (in case of statistically significant values) correspond to the 95% CI for that cut-off. The thicker vertical lines contain two index scores that almost overlap. Logistic regression analysis was employed with belimumab (10 mg/kg; reference comparator: placebo) as the outcome and each EQ-5D-3L cut-off as the predictor. EQ-5D-3L: three-level version of the EuroQol 5-Dimensions; OR: odds ratio